Hofseth Biocare ASA: FOURTH QUARTER 2022 & FULL YEAR FINANCIAL REPORT
10. Februar 2023 02:00 ET
|
Hofseth Biocare ASA
In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to...
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
30. Dezember 2022 04:08 ET
|
Hofseth Biocare ASA
Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider...
Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT
11. November 2022 02:00 ET
|
Hofseth Biocare ASA
Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon...
Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT
17. Oktober 2022 03:24 ET
|
Hofseth Biocare ASA
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...
Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
30. August 2022 08:25 ET
|
Hofseth Biocare ASA
The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the...
Hofseth Biocare ASA: HBC’S PROGO BIOACTIVE PEPTIDES NOW IS A “NEW DIETARY INGREDIENT” (NDI) FOR THE US FDA
29. August 2022 02:44 ET
|
Hofseth Biocare ASA
Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights...
Hofseth Biocare ASA: SECOND QUARTER & H1 2022 FINANCIAL REPORT
26. August 2022 02:00 ET
|
Hofseth Biocare ASA
HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of sales (CoGS) amounted to NOK 17.7m (21.6m) in the...
Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
09. August 2022 13:30 ET
|
Hofseth Biocare ASA
An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 30 August 2022 at 13:00 CET. Please find the notice to the General...
Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
04. August 2022 06:09 ET
|
Hofseth Biocare ASA
In the annual general meeting of Hofseth BioCare ASA (the "Company") held on 29 April 2022, the general meeting resolved to carry out a private placement towards Brilliant Invest 2 AG as part of an...
Hofseth Biocare ASA: JON OLAV ØDEGÅRD APPOINTED NEW CEO OF HBC
29. Juli 2022 02:00 ET
|
Hofseth Biocare ASA
Following years of strong growth in Hofseth International AS ("Hofseth International") and the expected further positive development in Hofseth BioCare ASA's ("HBC") revenues and sales activities, it...